Haleon PLC Sponsored ADR (NYSE:HLN) Shares Sold by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. trimmed its position in Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 47.7% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 94,129 shares of the company's stock after selling 85,767 shares during the period. Envestnet Portfolio Solutions Inc.'s holdings in Haleon were worth $969,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. QRG Capital Management Inc. grew its stake in Haleon by 38.5% in the first quarter. QRG Capital Management Inc. now owns 451,968 shares of the company's stock worth $4,651,000 after purchasing an additional 125,612 shares in the last quarter. Janney Montgomery Scott LLC grew its stake in Haleon by 4.6% in the first quarter. Janney Montgomery Scott LLC now owns 889,394 shares of the company's stock worth $9,152,000 after purchasing an additional 38,831 shares in the last quarter. Optas LLC grew its stake in Haleon by 17.9% in the first quarter. Optas LLC now owns 21,337 shares of the company's stock worth $220,000 after purchasing an additional 3,240 shares in the last quarter. Opal Wealth Advisors LLC acquired a new position in Haleon in the first quarter worth about $29,000. Finally, Wealth Enhancement Advisory Services LLC grew its stake in Haleon by 18.7% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 94,748 shares of the company's stock worth $975,000 after purchasing an additional 14,935 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on HLN. Barclays reissued an "overweight" rating on shares of Haleon in a report on Tuesday, May 6th. BNP Paribas raised shares of Haleon to a "strong-buy" rating in a report on Tuesday, May 27th. BNP Paribas Exane raised Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price target on the stock in a report on Tuesday, May 27th. Morgan Stanley raised Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price target on the stock in a report on Friday, May 9th. Finally, Wall Street Zen raised Haleon from a "hold" rating to a "buy" rating in a report on Friday, June 6th. Five analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $12.33.

Haleon Price Performance

NYSE:HLN traded up $0.03 during midday trading on Wednesday, hitting $10.52. 16,203,558 shares of the stock were exchanged, compared to its average volume of 9,230,257. Haleon PLC Sponsored ADR has a one year low of $8.25 and a one year high of $11.42. The company has a market capitalization of $47.31 billion, a price-to-earnings ratio of 26.98, a P/E/G ratio of 2.99 and a beta of 0.31. The business has a 50-day moving average price of $10.71 and a two-hundred day moving average price of $10.12. The company has a current ratio of 0.98, a quick ratio of 0.78 and a debt-to-equity ratio of 0.53.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.